Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators propose to explore the hypothesis-supported by limited data-that a contraceptive vaginal ring (CVR) that is commonly used in the United States, the NuvaRing, will enhance women's genital and reproductive health. The investigators propose that this CVR will increase the bacteria that help the vaginal environment protect against infection by HIV and other STIs, and that in women who already have HIV, use of the CVR will lower the quantity of HIV that is shed in the female genital tract.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Treatments: Contraceptive Agents; Desogestrel; Ethinyl Estradiol; NuvaRing

Criteria

Inclusion Criteria:

• BV+ by Amsel Criteria

• Not intending to become pregnant over the course of the study

• If HIV infected, not taking ART

• Capable of providing written informed consent

Exclusion Criteria:

• Current pregnancy

• Desire/intent to become pregnant over the course of the study

• Contraindications to hormonal contraceptive use

• Current cigarette smoking if age is older than 35 years

• Unable to comprehend consent material because of language barrier or psychological difficulty